Valmark Advisers’s Celularity CELU Stock Holding History

Valmark Advisers’s Portfolio CELU Stock Details CELU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-49,983	Closed	-$66.5K	–	730
2026 Q1	$66.5K	Hold	49,983	–	–	﹤0.01%	677
2025 Q4	$55.5K	Hold	49,983	–	–	﹤0.01%	657
2025 Q3	$103K	Hold	49,983	–	–	﹤0.01%	644
2025 Q2	$98K	Buy	+49,983	New	+$90.9K	﹤0.01%	639

Other funds holding CELU

CVSC

C.V. Starr & Co New York $187M AUM 26.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BFO

Biltmore Family Office Charlotte, North Carolina $761M AUM 31.91% 1-Year Est. Return

Valmark Advisers's CELU Position: Q2 2026 in Review

Valmark Advisers sold out of Celularity (CELU) in Q2 2026, closing a stake of 49,983 shares — an estimated $66.5K sold.

Valmark Advisers first reported a position in CELU in Q2 2025 and held it in 4 quarters. The position peaked at $103K in Q3 2025. 39 funds tracked by Wall St. Rank hold CELU as of Q2 2026.

Valmark Advisers reported no remaining Celularity position as of Q2 2026 after selling out during the quarter.
Valmark Advisers sold 49,983 Celularity shares in Q2 2026, an estimated $66.5K.
Valmark Advisers first reported a position in Celularity in Q2 2025 and held it in 4 quarters.
Valmark Advisers's Celularity position peaked at $103K in Q3 2025.
39 funds tracked by Wall St. Rank held Celularity as of Q2 2026.

Based on Valmark Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.